Saltar al contenido
Merck

Subtype-Directed Differentiation of Human iPSCs into Atrial and Ventricular Cardiomyocytes.

STAR protocols (2020-10-29)
Mandy Kleinsorge, Lukas Cyganek
RESUMEN

The generation of homogeneous populations of subtype-specific cardiomyocytes derived from human induced pluripotent stem cells (hiPSCs) is crucial in cardiovascular disease modeling as well as in drug discovery and cardiotoxicity screenings. This protocol describes a simple, robust, and efficient monolayer-based differentiation of hiPSCs into defined atrial and ventricular cardiomyocytes. For complete details on the use and execution of this protocol, please refer to Cyganek et al., 2018.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-α-actinina (sarcomérica) monoclonal antibody produced in mouse, clone EA-53, ascites fluid
Sigma-Aldrich
Dihexadecyldimethylammonium bromide, 97%
Sigma-Aldrich
Anti-RYR2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution